Free tool
FAERS Monitor: Cleocin Phosphate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050441 or its brand name (Cleocin Phosphate, Clindamycin Phosphate). Reports on generic versions are filed under their own applications.
Reports
3,596
Serious
2,284
64% of reports
Hospitalization
1,058
Death reported
270
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective373
- rash259
- drug hypersensitivity231
- off label use228
- diarrhoea192
- nausea190
- fatigue171
- pruritus169
- pain164
- condition aggravated135
- dyspnoea116
- headache114
- pyrexia110
- product use in unapproved indication109
- vomiting103
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 19 |
| 2005 | 53 |
| 2006 | 59 |
| 2007 | 14 |
| 2008 | 20 |
| 2009 | 43 |
| 2010 | 86 |
| 2011 | 66 |
| 2012 | 99 |
| 2013 | 102 |
| 2014 | 103 |
| 2015 | 125 |
| 2016 | 246 |
| 2017 | 184 |
| 2018 | 237 |
| 2019 | 281 |
| 2020 | 210 |
| 2021 | 194 |
| 2022 | 288 |
| 2023 | 305 |
| 2024 | 287 |
| 2025 | 309 |
| 2026 | 264 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,563 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug hypersensitivitySignal | 231 | 7.0 | 6.2 | 1,189 |
| rashSignal | 259 | 3.5 | 3.1 | 464 |
| condition aggravatedSignal | 135 | 2.6 | 2.2 | 133 |
| product use in unapproved indicationSignal | 109 | 2.6 | 2.1 | 104 |
| pruritusSignal | 169 | 2.6 | 2.2 | 164 |
| pyrexia | 110 | 1.9 | 1.5 | 44 |
| diarrhoea | 192 | 1.7 | 1.5 | 62 |
| drug ineffective | 373 | 1.7 | 1.5 | 103 |
| pain | 164 | 1.6 | 1.3 | 34 |
| off label use | 228 | 1.5 | 1.3 | 42 |
| nausea | 190 | 1.4 | 1.2 | 23 |
| fatigue | 171 | 1.3 | 1.1 | 11 |
| vomiting | 103 | 1.3 | 1.1 | 6 |
| dyspnoea | 116 | 1.2 | 1.0 | 4 |
| headache | 114 | 1.1 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.